{
    "clinical_study": {
        "@rank": "1306", 
        "arm_group": {
            "arm_group_label": "Myofascial trigger point", 
            "arm_group_type": "Experimental", 
            "description": "Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether a topical nitroglycerine patch applied\n      daily over a trapezius trigger point can improve patients' symptoms.\n\n      If there is improvement, this open label study will help determine the degree of improvement\n      and contribute to the design of a larger double blind placebo controlled trial.\n\n      We would consider moving forward to a large randomized trial if:\n\n        -  The intervention is acceptable to patients (>= 70%) and\n\n        -  Compliance is satisfactory (>=80%) and\n\n        -  We find preliminary evidence of efficacy, i.e. average reduction in pain of 20mm on the\n           VAS."
        }, 
        "brief_title": "Topical Nitrates for Myofascial Trigger Points", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": "Myofascial Trigger Points", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inclusion criteria include age between 19 and 65 years old, myofascial pain lasting\n             at least 6 months, and a myofascial trigger point point in the trapezius muscle.\n\n        Exclusion Criteria:\n\n          -  Our exclusion criteria include symptomatic disc herniation, symptomatic cervical\n             osteoarthritis, systemic infection, malignancy, collapsed vertebra, thoracic outlet\n             syndrome, temporomandibular joint dysfunction, collagen-vascular disease, or brachial\n             plexopathy. Patients with ongoing litigation regarding their symptoms are not\n             eligible for this study. Also excluded are patients with underlying cardiac disease,\n             hypotension, or medical conditions that may not allow them to tolerate the use of\n             vasodilators, and those who use phosphodiesterase inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675700", 
            "org_study_id": "122975"
        }, 
        "intervention": {
            "arm_group_label": "Myofascial trigger point", 
            "description": "Nitroglycerin 0.1 mg/hr patch", 
            "intervention_name": "Nitroglycerin patch", 
            "intervention_type": "Drug", 
            "other_name": "Nitro-Dur 0.1"
        }, 
        "intervention_browse": {
            "mesh_term": "Nitroglycerin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Myofascial pain", 
            "Trigger point", 
            "Nitroglycerin"
        ], 
        "lastchanged_date": "August 28, 2012", 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "University of British Columbia", 
            "last_name": "Hubert A Anton, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pain at the time of clinic visit and over the previous week as measured by a Visual Analog Scale, VAS, for pain and a pressure algometer measurement to obtain pressure pain thresholds over the patients trigger point.", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675700"
        }, 
        "responsible_party": {
            "investigator_affiliation": "GF Strong Rehabilitation Centre", 
            "investigator_full_name": "Anibal Bohorquez", 
            "investigator_title": "Medical Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "As another secondary outcome we will ask the participants whether the benefits of the treatment are good enough that they would continue using the nitroglycerin patch. This will be a yes or no response.", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "GF Strong Rehabilitation Centre", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GF Strong Rehabilitation Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}